MODERNA INC (1MRNA.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1MRNA - US60770K1079 - Common Stock
1MRNA.MI Key Statistics, Chart & Performance
The current stock price of 1MRNA.MI is 34.505 EUR. In the past month the price increased by 66.89%. In the past year, price decreased by -0.79%.
1MRNA.MI Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to 1MRNA.MI. When comparing the yearly performance of all stocks, 1MRNA.MI is one of the better performing stocks in the market, outperforming 83.99% of all stocks.
1MRNA.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1MRNA.MI. The financial health of 1MRNA.MI is average, but there are quite some concerns on its profitability.
1MRNA.MI Financial Highlights
Over the last trailing twelve months 1MRNA.MI reported a non-GAAP Earnings per Share(EPS) of -6.94. The EPS decreased by -38.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.68% | ||
| ROE | -33.4% | ||
| Debt/Equity | 0 |
1MRNA.MI Forecast & Estimates
30 analysts have analysed 1MRNA.MI and the average price target is 29.78 EUR. This implies a price decrease of -13.7% is expected in the next year compared to the current price of 34.505.
For the next year, analysts expect an EPS growth of 11.47% and a revenue growth -40.97% for 1MRNA.MI
1MRNA.MI Ownership
1MRNA.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 65.33 | 43.00B | ||
| ARGX.BR | ARGENX SE | 64.94 | 42.74B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.53B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.09B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.95B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.94B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.92B | ||
| IVA.PA | INVENTIVA SA | N/A | 1.07B | ||
| 6IV.DE | INVENTIVA SA | N/A | 962.73M | ||
| NANO.PA | NANOBIOTIX | N/A | 887.16M | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| PHIL.MI | PHILOGEN SPA | 18.99 | 633.05M |
Related stock screener links
About 1MRNA.MI
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Company Info
MODERNA INC
325 Binney Street
Cambridge MASSACHUSETTS US
Employees: 5800
Phone: 16177146500
MODERNA INC / 1MRNA.MI FAQ
Can you describe the business of MODERNA INC?
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
What is the current price of 1MRNA stock?
The current stock price of 1MRNA.MI is 34.505 EUR. The price decreased by -0.43% in the last trading session.
What is the dividend status of MODERNA INC?
1MRNA.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1MRNA stock?
1MRNA.MI has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is MODERNA INC (1MRNA.MI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1MRNA.MI.
How many employees does MODERNA INC have?
MODERNA INC (1MRNA.MI) currently has 5800 employees.